-
The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)-Prevenzione trial demonstrated a lower mortality rate in post myocardial infarction patients treated with n-3 polyunsaturated fatty acids (PUFA) vs controls, which was mainly due to a reduction in sudden death.
-
In this paper, Adabag et al from the Mayo Clinic analyzed the risk of sudden death after an acute myocardial infarction over a 28-year period in patients residing in Olmsted County, MN.
-
-
Prasugrel, a novel third-generation oral thienopyridine (following ticlopidine and clopidogrel), has recently been shown to provide clinically important platelet inhibition in acute coronary syndromes (ACS), with decreased ischemic events compared to clopidogrel in the TRITON-TIMI 38 trial of almost 14,000 ACS patients undergoing PCI.
-
Coronary artery stenoses involving the proximal left anterior descending coronary artery (LAD) have caused significant concern for clinicians over the years. If these lesions give rise to a myocardial infarction, this is often termed the "widow maker" because of the large area of myocardium subtended by the LAD and the high mortality associated with proximal LAD occlusion.
-
Unfractionated Heparin (UFH) is the standard bridging therapy for patients with mechanical heart valves who need to temporarily stop oral anticoagulants. Small case series have suggested that low molecular weight heparin (LMWH) may be useful for this purpose.
-
-
5-α reductase inhibitors and hip fracture in men; the effects of drug-reimbursement policy on outcomes; new guidelines for type 2 diabetes; beta-blocker-associated brady-cardia is linked to CVD events; FDA Updates.
-
Soft-tissue rheumatism often is a challenging disorder for the primary care physicians. The patient's symptoms often are vague, and the physical examination and laboratory testing often do not give comforting confirmatory findings. This issue reviews common conditions that afflict many of our patients and that, although often not serious, cause significant distress and morbidity. With the proper history and attention to presenting features, effective and professionally rewarding treatments are available.
-
5-α reductase inhibitors and hip fracture in men; the effects of drug-reimbursement policy on outcomes; new guidelines for type 2 diabetes; beta-blocker-associated brady-cardia is linked to CVD events; FDA Updates.
